Hansoh Pharma stock: Phase 3 data strengthen oncology pipeline
Published on 10/30/2026 at 02:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical data sharpen pipeline focus
- Hansoh Pharma said its Ris-Rez study met its primary progression-free-survival endpoint in heavily pretreated osteosarcoma patients.
- The company is developing the antibody-drug conjugate across several tumor types while GSK holds rights outside selected Greater China markets.
Hansoh Pharma said on October 27, 2026, that its risvutatug rezetecan candidate, also known as Ris-Rez or HS-20093, met the primary endpoint in the Phase 3 ARTEMIS-011 study. The announcement was issued by Hansoh Pharma after the data were presented at the 2026 ESMO Congress.
Phase 3 study delivers measurable benefit
The randomized study included 122 patients with relapsed or refractory osteosarcoma after at least two previous lines of therapy. Based on blinded independent central review, median progression-free survival was 5.5 months for Ris-Rez versus 1.4 months for gemcitabine plus docetaxel. The hazard ratio was 0.33, with a p-value below 0.0001.
The company also reported an objective response rate of 15% versus 2% and a disease-control rate of 76% versus 33%. Overall-survival data remain immature, so the result primarily strengthens the candidate's evidence on disease control rather than establishing a completed survival benefit.
Pipeline progress meets development risk
Ris-Rez is a B7-H3-directed antibody-drug conjugate with a topoisomerase I inhibitor payload. Hansoh is evaluating it in several cancer settings, while GSK holds exclusive rights to develop and commercialize it outside mainland China, Hong Kong, Macau and Taiwan. Further regulatory and clinical steps therefore remain important before the data can translate into commercial revenue.
The Lang & Schwarz quote for Hansoh Pharma was 3.77 euros on October 29, 2026, at 22:59:56 Berlin time. Investors should distinguish this European quote from the Hong Kong listing and avoid treating the clinical announcement as proof of a particular share-price reaction. The real-time quote of Hansoh Pharma stock provides the current market reference.
Hansoh Pharma stock at a glance
- Company: Hansoh Pharmaceutical Group Company Limited
- ISIN: KYG549581067
- Hong Kong ticker: 03692.HK
- Latest Lang & Schwarz quote: 3.77 euros, October 29, 2026, 22:59:56 Berlin time
- Primary topic: Phase 3 ARTEMIS-011 results for Ris-Rez in relapsed or refractory osteosarcoma
Broader market sentiment can be followed through the Euro Stoxx 50.
